Korro Bio, Inc.
KRRO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001703647
Insider trades, last 90 days
1 buy · 8 sells
- Bought $78.81K
- Sold $2.82M
- Open-market purchases (P) and sales (S), counted by Form 4 filing.
13F holders, Q2 2026
106
- +7 vs. Q1 2026
- Total value $198.81M
Superinvestors holding KRRO
0
- None of the superinvestors held KRRO at the end of Q2 2026.
Price chart
Latest insider trades
View all: Latest insider tradesOpen-market purchases and sales by KRRO insiders, newest first.
| Filed (ET) | Trade date | Insider | Transaction | Shares | Avg price | Value | Shares after | Holding change | Filing |
|---|---|---|---|---|---|---|---|---|---|
| Sep 15, 20264:15 PM ET | Sep 11 – Sep 14, 2026 | FORMELA JEAN FRANCOISDirector | SSaleCommon Stock | −48.69K | $14.0928 | −$686.18K | 132.65K | −26.9% | SEC10b5-1 |
| Sep 14, 20264:05 PM ET | Sep 11, 2026 | Dolan OliverSenior Vice President, Finance | SSaleCommon Stock | −5 | $13.716 | −$68.58 | 16.24K | 0.0% | SEC10b5-1 |
| Sep 10, 20264:05 PM ET | Sep 8 – Sep 9, 2026 | Dolan OliverSenior Vice President, Finance | SSaleCommon Stock | −7.35K | $13.5139 | −$99.37K | 16.25K | −31.2% | SEC10b5-1 |
| Aug 28, 20264:30 PM ET | Aug 26, 2026 | FORMELA JEAN FRANCOISDirector | SSaleCommon Stock | −300 | $13.96 | −$4.19K | 141K | −0.2% | SEC10b5-1 |
| Aug 21, 20264:20 PM ET | Aug 19, 2026 | FORMELA JEAN FRANCOISDirector | SSaleCommon Stock | −28.47K | $14.00 | −$398.55K | 141.05K | −16.8% | SEC10b5-1 |
Top 5 13F holders, Q2 2026
View all: Top 5 13F holders, Q2 2026The largest institutional positions in KRRO at the end of Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Lynx1 Capital Management LP | 1,538,296 | $20.27M | 2.34% | 00.0% | Unchanged |
| Nantahala Capital Management, LLC | 1,320,072 | $17.4M | 0.53% | +660,036+100.0% | Added |
| NEA Management Company, LLC | 1,297,893 | $17.11M | 1.08% | 00.0% | Unchanged |
| VR Adviser, LLC | 1,009,500 | $13.31M | 0.40% | 00.0% | Unchanged |
| Atlas Venture Life Science Advisors, LLC | 962,884 | $12.69M | 1.44% | −174,265−15.3% | Reduced |